IssaF.KhouriMD

Oncology • Houston, TX

Hematologic Oncology

Physician

Join to view full profile

Dr. Khouri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Khouri's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1990 - 1993
St Elizabeth Youngstown Hospital/NEOMEDResidency, Internal Medicine, 1987 - 1989
St Elizabeth Youngstown HospitalInternship, Transitional Year, 1986 - 1987
Sapienza University of RomeClass of 1983

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 1990 - 2026
OK State Medical License 2020 - 2021
OH State Medical License 1988 - 2000
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia Start of enrollment: 1995 Dec 01
Completed
Phase 1, Phase 2
Safety and Efficacy of Campath in Nonmyeloablative Transplantation Start of enrollment: 2001 Jun 01
Completed
Not Applicable
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies Start of enrollment: 2001 Apr 09
Terminated
Not Applicable
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies Start of enrollment: 2002 Oct 01
Completed
Phase 1, Phase 2
Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation Start of enrollment: 2006 Sep 01
Completed
Phase 1
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant Start of enrollment: 2007 Feb 13
Completed
Phase 2
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma Start of enrollment: 2003 Mar 01
Terminated
Phase 2
Non-Myeloablative Allogeneic Stem Cell Transplantation Start of enrollment: 2005 Jan 01
Completed
Not Applicable
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies Start of enrollment: 2007 Sep 01
Completed
Phase 2
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation Start of enrollment: 2007 Nov 14
Completed
Phase 2
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant Start of enrollment: 2009 Feb 17
Completed
Phase 1
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2009 May 06
Terminated
Phase 2
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas Start of enrollment: 2011 Aug 22
Completed
Phase 2
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) Start of enrollment: 2013 Jan 01
Completed
Phase 2
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies Start of enrollment: 2013 Nov 04
Completed
Phase 2
Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL) Start of enrollment: 2014 Jun 17
Completed
Phase 1
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation Start of enrollment: 2019 Oct 28
Recruiting
Phase 2
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant Start of enrollment: 2020 Mar 13
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving i...
Jayastu Senapati, Elias Jabbour, Nicholas J Short, Nitin Jain, Fadi Haddad
Blood Cancer Journal. 2024-08-07
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis.
Alexandre E Malek, Taha Al-Juhaishi, Denái R Milton, Jeremy L Ramdial, May Daher
Bone Marrow Transplantation. 2024-05-01
1 citations
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center pha...
Issa F Khouri, Kamal Alzahrani, Hagop Kantarjian, Denái R Milton, Alison M Gulbis
American Journal of Hematology. 2024-05-01

Journal Articles

Pilot Study Using Post-Transplant Cyclophosphamide (PTCy), Tacrolimus and Mycophenolate GVHD Prophylaxis for Older Patients Receiving 10/10 HLA-Matched Unrelated Donor...
Uday R Popat, Amin Alousi, Issa F Khouri, Muzaffar Qazilbash, Richard E Champlin, Partow Kebriaei, Simrit Parmar, Chitra Hosing, Nature
Impact of a Novel Prognostic Model, Hematopoietic Cell Transplant-Composite Risk (HCT-CR), on Allogeneic Transplant Outcomes in Patients with Acute Myeloid Leukemia an...
Uday Popat, Chitra M Hosing, Issa Khouri, Richard Champlin, Simrit Parmar, Partow Kebriaei, Borje S Andersson, Qaiser Bashir, Amin Alousi, Nature

Abstracts/Posters

Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study
Issa F. Khouri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation
Issa F. Khouri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS
Issa F. Khouri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression
Issa F. Khouri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...
Issa F. Khouri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receivi...
Issa F. Khouri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Do...
Issa F. Khouri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

IssaF.KhouriMD

Dr. Khouri is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.